When topical Rx therapies are not enough, choose DUPIXENT as your first-line systemic therapy for patients as young as 6 months of age with uncontrolled moderate-to-severe atopic dermatitis. DUPIXENT is the first and only biologic approved for the treatment of patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. With DUPIXENT, see what's possible for your patients whose disease remains uncontrolled.


CONTRAINDICATION: DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients.

Please see below for full Indication and additional Important Safety Information.